MAIA Biotechnology (MAIA) Research & Development (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Research & Development of $3.5 million for Q1 2026, up 10.24% year-over-year from $3.2 million in Q1 2025, and up 87.34% quarter-over-quarter from $1.9 million in Q4 2025.
MAIA Biotechnology (MAIA) Research & Development (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Research & Development for 6 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 10.24% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $14.9 million (up 36.64% YoY), while the FY2025 annual figure was $14.5 million, up 45.34% from the prior year.
- Research & Development grew to $3.5 million in Q1 2026 per MAIA's latest filing, from $1.9 million in the prior quarter.
- Across five years, Research & Development topped out at $6.4 million in Q3 2025 and bottomed at $1.9 million in Q4 2025.
- Historically, Research & Development has averaged $2.8 million across 5 years, with a median of $2.6 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development jumped 229.12% — and 2025, when it slumped 36.63%.
- MAIA Biotechnology's Research & Development stood at $2.4 million in 2022, then jumped by 55.32% to $3.7 million in 2023, then dropped by 20.13% to $3.0 million in 2024, then slumped by 36.63% to $1.9 million in 2025, then soared by 87.34% to $3.5 million in 2026.
- Business Quant data shows MAIA's Research & Development at $3.5 million in Q1 2026, $1.9 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | 5.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.64 Mn |
| Mar 31, 2026 | 3.53 Mn |
| Dec 31, 2025 | 1.88 Mn |
| Sep 30, 2025 | 6.36 Mn |
| Jun 30, 2025 | 3.11 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 2.32 Mn |
| Dec 31, 2023 | 3.72 Mn |
| Sep 30, 2023 | 2.60 Mn |
| Jun 30, 2023 | 2.60 Mn |
| Mar 31, 2023 | 2.20 Mn |
| Dec 31, 2022 | 2.39 Mn |
| Sep 30, 2022 | 2.34 Mn |
| Jun 30, 2022 | 2.12 Mn |
| Mar 31, 2022 | 2.08 Mn |
| Dec 31, 2021 | 1.51 Mn |
| Sep 30, 2021 | 1.08 Mn |